Pyrogen Testing Market Development And Business Intelligence
Summary
- Major factors influencing the growth of the market.
- Leading players & Business Strategies.
- Geographic Overview.
Market growth influenced due to following factors-
- The growing focus on personalized medicine.
- Increasing R&D in the pharmaceutical and biotechnology industries.
- Rising prevalence of chronic diseases, the growing awareness of food safety.
Global market size-
According to research report global pyrogen testing market size is projected to reach USD 1,689 million by 2025 from USD 927 million in 2020, at a CAGR of 12.7%.
Leading Players-
The major players operating in this pyrogen testing market are Charles River Laboratories, Inc. (US), Lonza (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), Associates of Cape Cod, Inc. (US), GenScript Biotech Corporation (CHINA), bioMérieux SA (France), FUJIFILM Wako Pure Chemical Corporation (Japan), Eurofins Scientific (Luxembourg), WuXi AppTec (CHINA), Hycult Biotech (Netherlands), Ellab A/S (Denmark), Microcoat Biotechnologie GmbH (Germany), InvivoGen (US), Nelson Laboratories, LLC (US), Almac Group (UK), Pacific Biolabs (US), STERIS plc (US), Accugen Laboratories, Inc. (US), TOXIKON (US), Minerva Analytix GmbH (Germany), Indoor Biotechnologies, Inc. (US), Creative Bioarray (US), Lucideon Limited (UK), and North American Science Associates, Inc. (US).
For details Download PDF Brochure Here
Geographic Overview -
The market is segmented into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2019, North America accounted for the largest share of the market.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.